The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Silverhorse, if it's hits 40p, I'm move to Cote d'Azur !!!! It's definitely possible ! Big news must be coming soon !!!! Sit tight and hold !
we seem to get a fair few sellers when it gets close to 10p - so many times it falls back but no so sure this time its holding up well, am so certain its going big one way or another so holding firm for 40p plus or if the **** hits the fan 2p
Yes delighted but unexpected. Thought today was going to be red waiting for news. No news but must be bubbling under
Mmm..sudden about turn from recent drift downwards...is something brewing or another false dawn? ๐ค
I think Poolbeg Pharma has become what was previously "Open Orphan" (before it aquired Hvivo) ๐ค as a lot of emphasis on Orphan Drug Development, if you carefully read the article from 'Who is Poolbeg Pharma?' A lot said about becoming 'Amryt Pharma 2' but definitely'Open Orphan' as well. Both positive I suppose. JMO Adyor!
Poolbeg Pharma specialises in the development of innovative medicines to address critical unmet medical needs.
This includes cancer immunotherapy-induced CRS, infectious diseases and metabolic conditions such as obesity with the development of an oral GLP-1R agonist.
The company is also placing a growing emphasis on rare and orphan diseases.
Poolbeg is focused on commercialising approved and marketed drugs to fund the development of future ground-breaking products in the immunotherapy space.
The notice of allowance from the US Patent Office for a #POLB 001 patent featured in @SmallCaps_UK
The claims cover the treatment & prevention of cytokine storm after an immune response has been triggered - in any disease indication
https://smallcaps.co.uk/poolbeg-pharma-closer-granting-patent-polb-001-treat-multiple-diseases/
Stop spouting more nonsense, I thought you were looking for 9p entry since you sold half your holdings in October. Make you mind up whether you ramping or not....
Alot of people follow him so would not be surprised to see this move up alot tomorrow, CF and tom will really blow this up - lets see
The guy is a complete tw^t
tom w (*************) is doing a podcast later today with cf. it will be interesting to hear when it is published.
gla.
NOPE ! No rise.
Closed period after director share purchase is well and truly over now so there will be no questions asked if any good news on partnership deals , mergers or acquisitions were to be announced. End of year results due shortly. We will see what we have left in the kitty, probably about a ยฃ10m cushion to carry us through to first revenues.
No. I hope you get your 9p buy in...
Moniman - Was that your 10 share buy 9.7p ?
As suspected,Silverhorse trimmed his 1.2 million holding down to 500k and looking to get back in again sub 9p...no surprise about the sudden change to negative from ultra positive back in October... ๐ค
It clear Silverhorse tries to regularly trade this share, going from ramping to deramping in quick succession. News will arrive when it arrives and the day traders will peddle nonsense in between times..JMO
Silver horse, what utter rubbish, it's not 60 days at all, imagine someone wanting to sign a deal with us now.... no sorry we cant do that, we have to wait 60 days as I just bought some shares hahaha
Make your deramping attempts a bit more clever next time
Its 60days here, did you see the larger sells yesterday 9p, should see a fall under 9p soon - any deal is months away anyway so relax
I'm expecting a rise on Monday when I would some of the savvy investors who sold out on the director buys, but back in.
Directors are typically in a blackout period 30 days before any known news or results publications and Monday is the first trading day back after this. We are back in the zone where "news could drop anytime"
Today's RNS has obviously not been taken seriously by anyone other than JS it seems? The only trouble with getting all of these patent protections for Polb-001, are they actually worth anything at all? I could take out a patent on a triangular shaped cricket ball, but is anyone likely going to buy such a product? ๐ค I doubt it. JMO
It's far more likely someone had a mental sell price of 10p and the price went above it, so they sold but that someone could always be an insider of course, like you - impossible to know and not worth dwelling on tbh
MaryB, good luck but as you say it doesn't always work out selling the peaks and buying the troughs, however I still think there is a remote possibility that some insider dealing could be going on here judging by the strange price movements either side of RNS's? I see that someone was prosecuted recently in the Republic of Ireland for using inside information to deal in Hvivo (Open Orphan) shares...I hope that the same isn't going on here! Evidence is almost impossible to gather, but it was proven in the case of Open Orphan. Don't get caught out by any sudden news ๐ ๐คฃ. JMO Adyor!
https://www.breakingnews.ie/ireland/first-man-in-states-history-found-guilty-of-insider-trading-after-gambling-retirement-fund-1567087.html
14p on chart by Zakmir
Biopharmaceutical company Poolbeg Pharma announced on Wednesday that it has received a notice of allowance from the US Patent Office regarding its immunomodulator II patent application.
This AIM-traded firm said the development pertained to POLB 001, a potent phase II-ready p38 MAP kinase inhibitor with promising applications across various disease domains.
It said the approved claims by the US Patent Office encompassed a class of drugs, including POLB 001, intended for the treatment of hypercytokinemia, or cytokine storm, and prevention of hypercytokinemia post-immune response activation, applicable to cytokine storms induced by any disease indication.
Poolbeg said it was actively bolstering its intellectual property portfolio with existing patents covering p38 MAP kinase inhibitors for severe influenza treatment and POLB 001 specifically for hypercytokinemia treatment.
Additionally, the company said it had filed further patent applications to broaden coverage, particularly in cancer immunotherapies, thus augmenting the value and appeal of POLB 001 to potential pharmaceutical partners.
"This notice of allowance is significant for Poolbeg, further strengthening our robust intellectual property for the company's exciting POLB 001 therapy and enhancing its value for potential partners," said chief executive officer Jeremy Skillington.
"POLB 001 has the potential to make breakthrough cancer immunotherapies more accessible to the patients that need them by enabling safer and broader use of these cancer treatments in an outpatient setting.
"I am excited by the potential of POLB 001 to positively impact global health, it has a compelling data package and there is strong unmet need for an effective therapy for cancer immunotherapy-induced cytokine release syndrome with the market potential in this setting alone exceeding $10bn."
It is quite simple although not without risk.